Patents by Inventor Bruce D. Jaffee

Bruce D. Jaffee has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • DOSING REGIMES FOR THE TREATMENT OF OCULAR VASCULAR DISEASE
    Publication number: 20130197016
    Abstract: The use of vascular endothelial growth factor receptor 2 inhibitors or a pharmaceutically acceptable salt thereof for the treatment of ocular vascular disease is provided. Dosing regimes, including once weekly administration, of certain VEGF-R2 inhibitors are provided which deliver therapeutically effective concentrations of the VEGF-R2 compounds in ocular tissues for at least one week for the treatment of ocular vascular disease.
    Type: Application
    Filed: October 25, 2011
    Publication date: August 1, 2013
    Inventors: Mitchell Brigell, Peter End, Vinayak Hosagrahara, Bruce D. Jaffee, Erik Meredith, Ronald Keith Newton, Stephen Poor, Yubin Qiu
  • Treatment of organ transplantation rejection
    Patent number: 5204329
    Abstract: 4-Quinoline-carboxylic acid derivatives, such as 2-(2'-fluoro-1,1'-biphenyl-4-yl)-6-fluoro-3-methyl-4-quinoline carboxylic acid, in combination with other immunosuppressive agents are useful for the treatment and/or prevention of transplantation rejection, graft vs. host disease, autoimmune diseases, and chronic inflammatory disease.
    Type: Grant
    Filed: June 11, 1990
    Date of Patent: April 20, 1993
    Assignee: Du Pont Merck Pharmaceutical Company
    Inventors: Neil R. Ackerman, Bruce D. Jaffee
  • 3-phenyl-5,6-dihydrobenziciacridine-7-carboxylic acids and related compounds as immunosuppressive agents
    Patent number: 5190753
    Abstract: Dihydrobenz[c]acridine carboxylic acid derivatives are provided which are useful for the treatment and/or prevention of organ transplantation rejection, graft versus host disease, autoimmune diseases, psoriasis and chronic inflammatory diseases.
    Type: Grant
    Filed: June 5, 1992
    Date of Patent: March 2, 1993
    Assignee: Du Pont Merck Pharmaceutical Company
    Inventors: Carl H. Behrens, Bruce D. Jaffee
  • Pyrimidine biosynthesis inhibitors useful as immunosuppressive agents
    Patent number: 5102883
    Abstract: The pyrimidine biosynthesis inhibitors dichloroallyl lawsone, N-(phosphonoacetyl)-L-aspartic acid (PALA), pyrazofurin, and derivatives thereof, are useful as immunomodulatory and anti-inflammatory agents. Pharmaceutical formulations containing these compounds are useful for the treatment of autoimmune diseases, chronic inflammatory diseases, and of organ transplantation rejections.
    Type: Grant
    Filed: October 31, 1989
    Date of Patent: April 7, 1992
    Assignee: Du Pont Merck Pharmaceutical Company
    Inventors: Neil R. Ackerman, Bruce D. Jaffee
  • 4-quinoline carboxylic acid derivatives useful as immunosuppressive agents
    Patent number: 5084462
    Abstract: 4-Quinolinecarboxylic acids and derivatives thereof, such as 2-(2'-fluoro-1,1'-biphenyl-4-yl)-6-fluoro-3-methyl-4-quinolinecarboxylic acid, are useful as immunodulatory and anti-inflammatory agents. Pharmaceutical formulations containing such compounds are useful for the treatment of autoimmune diseases, organ transplantation rejection, graft vs. host disease, multiple sclerosis, and chronic inflammatory diseases such as rheumatoid arthritis.
    Type: Grant
    Filed: June 28, 1990
    Date of Patent: January 28, 1992
    Assignee: The Du Pont Merck Pharmaceutical Company
    Inventors: Neil R. Ackerman, Bruce D. Jaffee, Scott E. Loveless, Russell H. Neubauer